Dosimetry in peptide receptor radionuclide therapy (PRRNT): comparative results using Lu-177 DOTA-TATE, DOTA-NOC und DOTA-TOC

被引：0
|
作者：
Schuchardt, C. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S244 / S244
页数：1
相关论文
共 50 条
  • [1] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S373 - S373
  • [2] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S179 - S179
  • [3] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [4] Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S178 - S179
  • [5] Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE
    Velikyan, Irina
    Xu, Hui
    Nair, Manoj
    Hall, Hakan
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2012, 39 (05) : 628 - 639
  • [6] Lu-177 DOTA-TATE for peptide receptor Radionuclide therapy (PRRT): Organ, tumor, and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S358 - S359
  • [7] Comparison of tumour and whole body absorbed doses of 177-Lu- DOTA-TATE and Lu-177 DOTA-NOC treatment in the same patient group
    Yeyin, N.
    Kabasakal, L.
    Akyel, R.
    Ocak, M.
    Toklu, T.
    Selcuk, N.
    Demir, M.
    Kanmaz, B.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S200 - S200
  • [8] Preliminary Results of Lu-177 DOTA-TATE Therapy in Patients with Neuroendocrine Tumor
    Hekimsoy, T.
    Isgoren, S.
    Gorur, G. Daglioz
    Demir, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S596
  • [9] Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long term follow-up
    Prasad, V.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S351 - S351
  • [10] Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application
    Das, Tapas
    Bhadwal, Mohini
    Banerjee, Sharmila
    Sarma, H. D.
    Shinto, Ajit
    Kamaleshwaran, K. K.
    [J]. JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2014, 299 (03) : 1389 - 1398
12345